LSD

What LSD Is

Lysergic acid diethylamide is a semi-synthetic compound built from lysergic acid, which comes in turn from alkaloids produced by the ergot fungus (Claviceps purpurea). It does not occur in nature in the form people take. That places it between the naturally occurring psychedelics and the fully synthetic ones, and the distinction is pharmacologically real: LSD runs longer, feels more stimulating, and has a somewhat different character from the plant and fungal tryptamines.

LSD is active at doses measured in micrograms, millionths of a gram, which makes it one of the most potent psychoactive substances known. A common dose is 75–150 micrograms, doses above 200 are high, and the curve between them is steep.

That potency determines what a reader actually encounters. There is far too little material in a dose to see or weigh, so LSD is always carried by something: a square of blotter paper, a drop of liquid, a gel tab, occasionally a sugar cube. You never handle the substance itself, only its carrier, and you have no way to judge by eye how much is on it. Almost everything practical about LSD follows from that single fact, including why blotter potency varies and why testing matters.

Where LSD Comes From

Every gram of LSD begins as lysergic acid, and lysergic acid begins as ergot alkaloids produced by a fungus. Historically that meant ergot grown on rye. Today it usually means Claviceps cultured in fermentation tanks for the legitimate pharmaceutical market, since ergot derivatives are still used in medicines for migraine and post-partum haemorrhage. Either way, the chain begins with something biological, which is what the word semi-synthetic is doing.

This matters practically because it makes the precursor a bottleneck. Ergot alkaloids are watched, and the synthesis is genuinely difficult rather than merely illegal. The result is that LSD production has always been concentrated in a small number of skilled operations rather than dispersed the way methamphetamine or cannabis production is. When one of them stops, supply across a whole continent thins out for a while.

Why two tabs from the same sheet are not the same dose

Blotter is made by dissolving crystal LSD in a solvent and laying that solution onto perforated paper, usually by dipping or spraying a whole sheet at once. Nothing about that process distributes the solution evenly. Squares near the edge of a sheet routinely carry more or less than squares in the middle, and the difference between the strongest and weakest tab from a single sheet can be substantial. A sheet advertised as 100 micrograms is a claim about an average at best, and frequently just a claim.

Liquid is more consistent in principle and less so in practice, because the concentration of a vial is unknown unless someone measured it, and a drop is not a controlled unit. People who want precision use volumetric dosing, diluting a known quantity into a known volume so a measured amount can be taken. That solves the arithmetic and leaves the original question of how much was in the vial to begin with.

The substitution problem

Blotter is the one form where a dangerous substitution is easy, and the reason is arithmetic. Very few compounds are active in the microgram range, so very few can be delivered on a paper square. The NBOMe series can. 25I-NBOMe and its relatives have been sold on blotter as LSD for over a decade. They are active at similar-looking doses, and they carry vasoconstriction, seizure risk, and a record of deaths that LSD does not have. The testing section covers how to separate them, and the crude version is worth knowing now: LSD is tasteless, NBOMes are markedly bitter and numb the tongue.

A separate category is the lysergamide analogues sold openly online as research chemicals, principally 1P-LSD, ALD-52, and 1V-LSD. These are largely prodrugs that convert to LSD in the body and produce a similar experience. They are not adulterants and are usually what they claim to be. Their significance is legal rather than pharmacological, and it is covered under legal status.

History & Cultural Roots

LSD has no nature card on this page, because a semi-synthetic compound has no ecological life of its own. What it has instead is a fungus with a long and terrible history, and that is where the story starts.

Ergot grows on rye, and rye fed medieval Europe. Outbreaks of ergotism recurred for centuries and came in two forms. One constricted blood vessels until limbs blackened and were lost, which is why it was called St. Anthony's Fire. The other produced convulsions, and in many accounts hallucinations and terror. Thousands died in single episodes. The same alkaloids that did that are the raw material LSD is made from, which is worth sitting with rather than skipping past.

Albert Hofmann, working at Sandoz in Basel, was investigating ergot derivatives for circulatory and obstetric medicine when he first synthesised lysergic acid diethylamide in 1938. It was the twenty-fifth compound in the series and it did nothing interesting in animal testing, so it was shelved. Five years later, in April 1943, he resynthesised it and absorbed a trace through his fingertips. On 19 April he deliberately took what he assumed was a cautious dose of 250 micrograms, which is several times a common dose, and cycled home from the laboratory with his assistant while it took hold. That ride is the reason 19 April is now called Bicycle Day.

Delysid and the first research era

Sandoz began marketing LSD as Delysid in 1947 and distributed it to researchers largely for free, suggesting two uses: as an adjunct to psychotherapy, and as a way for clinicians to experience something like psychosis themselves. Over the following two decades it generated over a thousand published papers and was given to tens of thousands of patients. European practice tended toward repeated low doses alongside analysis. North American practice tended toward single high doses aimed at a decisive experience. The word psychedelic itself dates from this period. The psychiatrist Humphry Osmond coined it in an exchange with Aldous Huxley, who had proposed the rather less durable "phanerothyme," and announced it at a meeting of the New York Academy of Sciences in 1957.

The same era produced MK-Ultra. From 1953 the CIA ran LSD experiments on people who had not consented and in many cases did not know they had been dosed, including prisoners, psychiatric patients, and its own staff. One of them, the army scientist Frank Olson, died in a fall from a hotel window days after being dosed without his knowledge. This is part of LSD's history rather than a footnote to it, and it did lasting damage to the credibility of the research that surrounded it.

Prohibition and return

By the early 1960s LSD had left the clinic. Timothy Leary and Richard Alpert were dismissed from Harvard in 1963, the counterculture adopted the drug as an emblem, and the political reaction was swift. Sandoz stopped distribution in 1965, the United States criminalised possession in 1968 and placed LSD in Schedule I in 1970, and the 1971 UN Convention closed the door internationally. Research stopped almost entirely for thirty years. It resumed in the 2000s, slowly and under conditions considerably more restrictive than those Sandoz had once handed out for free.

Pharmacology

Like psilocybin and DMT, LSD acts primarily as a serotonin 5-HT2A receptor agonist. However, LSD has a broader receptor binding profile, it also binds with high affinity at dopamine D2, adrenergic, and other serotonin receptor subtypes, which accounts for its more stimulating, energising character compared to psilocybin.

A distinctive pharmacological feature of LSD is its "kinetic trapping" at the receptor: an LSD molecule, once bound to the 5-HT2A receptor, is covered by a "lid" formed by a loop of the receptor protein and is released very slowly, a mechanism discovered by Wacker and colleagues (2017) that explains LSD's uniquely long duration of action compared to other tryptamines.

Effects

Onset (30–90 minutes)

Gradual onset with early signs: tingling, alertness, mild perceptual brightening, slight anxiety or anticipation. The onset is slower than psilocybin and less characterised by the body weight and warmth sensations common in mushroom experiences.

Ascent and peak (3–6 hours)

LSD's peak is broad and extended rather than sharp. Perceptual effects are prominent: visual patterns and tracers are typically more crisp and geometric than psilocybin. Thought acceleration and a stimulant-like quality are characteristic. LSD is more cognitively activating, many people find it more difficult to rest or surrender during an LSD experience than a mushroom one.

Plateau and long tail (6–10+ hours)

LSD's total duration (8–12 hours, sometimes longer) is its most significant practical distinction from psilocybin. The extended plateau means the experience demands more physical and psychological endurance. Sleep is typically impossible for 10–14 hours after a moderate dose. Planning accordingly, ensuring the following day is unencumbered, is essential.

Afterglow

A clear, reflective quality often persists for 12–24 hours. Some people find this afterglow more productive for integration than psilocybin's, others find the residual stimulation disruptive.

Dosage Reference

LSD doses are measured in micrograms (μg). Street tabs of unknown origin are notoriously variable, testing is essential. See the testing section below.

LSD vs. Psilocybin: Key Differences

Duration. LSD: 8–12 hours. Psilocybin: 4–6 hours. This is the single most important practical difference. LSD demands greater stamina and more careful scheduling.

Character. LSD tends to be more stimulating, cerebral, and visually crisp. Psilocybin tends to be warmer, more emotionally directive, and more body-centred. LSD is less likely to produce the surrender and dissolution that characterises the deepest mushroom experiences, though at high doses, the distinction diminishes.

Ecological phenomenology. Both substances produce ecological and relational themes, though psilocybin produces them more consistently and with greater emotional intensity in the empirical literature. LSD's cognitive activation may actually make ecological attunement more difficult to access at moderate doses.

Clinical research. Psilocybin has a substantially larger and more recent clinical evidence base. LSD research was effectively frozen from the early 1970s until recent years, though studies at Imperial College and in Switzerland have resumed.

Research on LSD

LSD was the first psychedelic to attract serious psychiatric research, beginning in the 1950s. Sandoz distributed LSD to researchers under the name Delysid throughout the 1950s and early 1960s, producing over 1,000 published papers before prohibition halted research.

Contemporary research has resumed cautiously. Liechti and colleagues in Basel have published pharmacological and dose-finding studies. Imperial College London's work under David Nutt and Robin Carhart-Harris has included LSD in neuroimaging and comparative studies. Research specifically on LSD-assisted psychotherapy is less advanced than psilocybin research, but the pharmacological similarities suggest therapeutic mechanisms are broadly comparable.

Risks and Harm Reduction

Adulteration. Street LSD is frequently misdosed, and some tabs sold as LSD contain NBOMe compounds or other substances. Testing is not optional, see below.

Duration-related risks. The extended duration means that a difficult experience lasts significantly longer than with psilocybin. Having an experienced sitter is especially valuable for first experiences.

HPPD. Hallucinogen Persisting Perception Disorder, persistent visual disturbances after the experience has ended, is rare but real. Risk appears to be dose-related and higher in people with pre-existing anxiety disorders.

Cardiovascular. LSD produces moderate increases in heart rate and blood pressure. Cardiac contraindications apply.

Psychological contraindications mirror psilocybin: personal or family history of schizophrenia spectrum disorders or bipolar I is a firm contraindication.

Testing Your Supply

Testing LSD is non-negotiable. The Ehrlich reagent turns purple in the presence of indole alkaloids, a positive result indicates an LSD-type compound is present. The Hofmann reagent is more specific for LSD. Crucially, neither test rules out the presence of additional substances.

The most reliable testing method is fentanyl test strips (for the ever-present contamination risk) combined with an Ehrlich reagent. Test kits are available from DanceSafe. In Canada, drug checking services in several cities offer more precise analysis.

The reason to bother is specific. Ehrlich detects indole alkaloids, and NBOMe compounds are not indoles, so blotter carrying 25I-NBOMe gives no purple where LSD would. A blank Ehrlich on something sold as LSD is therefore a strong signal to discard it rather than an inconclusive one. Test a corner of the tab rather than the whole thing, and remember that a positive tells you an indole is present, not how much.

The taste check is worth keeping as a backstop for the moment a tab is already on your tongue. LSD has essentially no taste. A distinctly bitter, metallic, or numbing square is a reason to spit and stop.

Legal Status

LSD is Schedule I under the 1971 UN Convention and prohibited in effectively every jurisdiction. It is Schedule I in the United States, Schedule III in Canada, and Class A in the United Kingdom. That much is uniform and briefly stated. Two things about it are not obvious and are worth more space.

Sentencing counts the paper

Because LSD is dosed in micrograms and carried on something, the question of what gets weighed has enormous consequences. United States federal law sets penalties by the weight of the "mixture or substance" containing a controlled drug, and in 1991 the Supreme Court held in Chapman v. United States that this includes the blotter paper. A sheet of paper weighs thousands of times more than the LSD on it, so the same number of doses could produce wildly different sentences depending on whether they sat on paper, gel, or sugar cubes.

The Sentencing Commission addressed this in 1993 by assigning a notional 0.4 milligrams per dose regardless of what the dose is carried on. That figure is still roughly eight times the amount of actual LSD in a typical dose, so the carrier is still being counted, just consistently. The practical upshot is that quantities that sound trivial in micrograms convert into serious weight-based charges, and LSD offences routinely carry penalties out of proportion to what most people assume.

The analogues are not a loophole any more

1P-LSD, ALD-52, and 1V-LSD have been sold openly online on the basis that they were not named in any schedule. That basis has largely eroded. The United Kingdom's blanket ban on psychoactive substances captured them from 2016, Germany's analogue legislation covers the group, and several other countries have named them explicitly. In the United States the Federal Analogue Act can reach a substantially similar compound intended for human consumption without it ever being scheduled by name.

Two consequences worth being clear about. Legality of these compounds is jurisdiction-specific and changes without much notice, so a vendor operating lawfully in one country says nothing about the country you are in. And a substance being purchasable is not evidence that it is legal to possess where you live. Check the legal quick reference and current local law rather than a vendor's own account of it.

If You Are Considering This

The general groundwork is on assessment, preparation, and integration. What is specific to LSD is almost entirely about time.

Budget two days, not one

Eight to twelve hours of effects, plus a tail that keeps most people awake well past when they would like to be asleep, plus a next day that is usually functional but not sharp. That is not an afternoon. Start early enough that the descent lands in the evening rather than at four in the morning, which in practice means taking it before mid-morning. An LSD dose taken after dinner commits you to being awake at sunrise, and doing that without having chosen it is one of the more reliably miserable experiences available.

Leave the following day clear. Not because you will be impaired, but because sleep will have been short and the residue is real. Plan nothing that requires you to be convincing.

Assume you do not know the dose

Everything in where it comes from means the number written on a sheet is not a measurement. With unfamiliar blotter, half a tab is a reasonable starting point, and the wait before deciding anything further should be at least two hours, because LSD's onset can be slow and uneven. Redosing LSD is rarely satisfying in any case, since tolerance builds within the experience itself and the added hours land on an already long day.

The long middle is where preparation earns itself

LSD's plateau is longer than the peak of most other psychedelics, and the difficulty people report is more often tedium, restlessness, or looping thought than acute fear. Having a plan for hours six through ten is worth more than anything you arrange for the first two. Somewhere to go outside, music chosen in advance, and a person who is not also dosed all help more than they sound like they should.

LSD asks for a cleared calendar more than any other substance covered here. Give it the whole day it is going to take, and most of what people find difficult about it stops being difficult.

FAQ